Linden Advisors’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

Linden Advisors’s Portfolio ORIA Stock Details ORIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-41,814	Closed	-$428K	–	486
2023 Q1	$428K	Hold	41,814	–	–	﹤0.01%	266
2022 Q4	$420K	Hold	41,814	–	–	﹤0.01%	349
2022 Q3	$411K	Hold	41,814	–	–	﹤0.01%	437
2022 Q2	$407K	Sell	41,814 -658,186	-94%	-$6.43M	﹤0.01%	468
2022 Q1	$6.82M	Buy	+700,000	New	+$6.79M	0.04%	269

Linden Advisors's ORIA Position: Q2 2023 in Review

Linden Advisors sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q2 2023, closing a stake of 41,814 shares — an estimated $428K sold.

Linden Advisors first reported a position in ORIA in Q1 2022 and held it in 5 quarters. The position peaked at $6.82M in Q1 2022. 0 funds tracked by Wall St. Rank hold ORIA as of Q2 2023.

Linden Advisors reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q2 2023 after selling out during the quarter.
Linden Advisors sold 41,814 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q2 2023, an estimated $428K.
Linden Advisors first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q1 2022 and held it in 5 quarters.
Linden Advisors's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $6.82M in Q1 2022.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q2 2023.

Based on Linden Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.